These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 12643107)

  • 1. New pharmacologic agents for diabetes.
    Bailey CJ
    Curr Diab Rep; 2001 Oct; 1(2):119-26. PubMed ID: 12643107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models.
    Etgen GJ; Oldham BA; Johnson WT; Broderick CL; Montrose CR; Brozinick JT; Misener EA; Bean JS; Bensch WR; Brooks DA; Shuker AJ; Rito CJ; McCarthy JR; Ardecky RJ; Tyhonas JS; Dana SL; Bilakovics JM; Paterniti JR; Ogilvie KM; Liu S; Kauffman RF
    Diabetes; 2002 Apr; 51(4):1083-7. PubMed ID: 11916929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes.
    Henke BR
    J Med Chem; 2004 Aug; 47(17):4118-27. PubMed ID: 15293980
    [No Abstract]   [Full Text] [Related]  

  • 4. Peroxisome proliferator-activated receptor (PPAR) gamma agonists for diabetes.
    Moller DE; Greene DA
    Adv Protein Chem; 2001; 56():181-212. PubMed ID: 11329854
    [No Abstract]   [Full Text] [Related]  

  • 5. [Evaluation of a thiazolidinedione compound as a new antidiabetic drug].
    Toyota T
    Nihon Rinsho; 2001 Nov; 59(11):2211-8. PubMed ID: 11712410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New approaches in the treatment of type 2 diabetes.
    Zhang BB; Moller DE
    Curr Opin Chem Biol; 2000 Aug; 4(4):461-7. PubMed ID: 10959776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New drugs for type 2 diabetes mellitus: what is their place in therapy?
    Krentz AJ; Patel MB; Bailey CJ
    Drugs; 2008; 68(15):2131-62. PubMed ID: 18840004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rosiglitazone treatment improves insulin regulation and dyslipidemia in type 2 diabetic cynomolgus monkeys.
    Gee MK; Zhang L; Rankin SE; Collins JN; Kauffman RF; Wagner JD
    Metabolism; 2004 Sep; 53(9):1121-5. PubMed ID: 15334371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel peroxisome proliferator-activated receptor ligands for Type 2 diabetes and the metabolic syndrome.
    Miller AR; Etgen GJ
    Expert Opin Investig Drugs; 2003 Sep; 12(9):1489-500. PubMed ID: 12943493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promising new approaches.
    Reasner CA
    Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin resistance and its treatment by thiazolidinediones.
    Lebovitz HE; Banerji MA
    Recent Prog Horm Res; 2001; 56():265-94. PubMed ID: 11237217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Future targets in the treatment of type 2 diabetes].
    Stingl H; Roden M
    Wien Klin Wochenschr; 2004 Apr; 116(7-8):217-29. PubMed ID: 15143860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experimental approaches to study PPAR gamma agonists as antidiabetic drugs.
    Vázquez M; Silvestre JS; Prous JR
    Methods Find Exp Clin Pharmacol; 2002 Oct; 24(8):515-23. PubMed ID: 12500431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Glitazones (thiazolidinedione)].
    Ducobu J; Sternon J
    Rev Med Brux; 2000 Oct; 21(5):441-6. PubMed ID: 11109896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacology of PPARalpha, PPARgamma and dual PPARalpha/gamma agonists in clinical development].
    Duran-Sandoval D; Thomas AC; Bailleul B; Fruchart JC; Staels B
    Med Sci (Paris); 2003; 19(8-9):819-25. PubMed ID: 14593612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel strategies for the pharmacological management of type 2 diabetes.
    Nourparvar A; Bulotta A; Di Mario U; Perfetti R
    Trends Pharmacol Sci; 2004 Feb; 25(2):86-91. PubMed ID: 15102494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of alpha-aryloxy-alpha-methylhydrocinnamic acids: a novel class of dual peroxisome proliferator-activated receptor alpha/gamma agonists.
    Xu Y; Rito CJ; Etgen GJ; Ardecky RJ; Bean JS; Bensch WR; Bosley JR; Broderick CL; Brooks DA; Dominianni SJ; Hahn PJ; Liu S; Mais DE; Montrose-Rafizadeh C; Ogilvie KM; Oldham BA; Peters M; Rungta DK; Shuker AJ; Stephenson GA; Tripp AE; Wilson SB; Winneroski LL; Zink R; Kauffman RF; McCarthy JR
    J Med Chem; 2004 May; 47(10):2422-5. PubMed ID: 15115385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drugs on the horizon for diabesity.
    Bailey CJ
    Curr Diab Rep; 2005 Oct; 5(5):353-9. PubMed ID: 16188170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mechanisms by which PPAR gamma modulators regulate insulin sensitivity].
    Yamauchi T; Kadowaki T
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():578-87. PubMed ID: 12387054
    [No Abstract]   [Full Text] [Related]  

  • 20. PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy?
    Larsen TM; Toubro S; Astrup A
    Int J Obes Relat Metab Disord; 2003 Feb; 27(2):147-61. PubMed ID: 12586994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.